News

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.
Sarepta Therapeutics announced it is laying off nearly 500 employees this week, including 80 at its Easton location.
The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene therapy for Duchenne muscular dystrophy.
Hearing that a second boy with Duchenne had died from liver failure after receiving Elevidys was a shock, said Kameron Lawson, speaking to STAT on Sunday night from their home in Stockton, Calif.